Locus Biosciences is a biotechnology company that develops CRISPR-Cas3-engineered precision antibacterial products. The company's products are designed to target and kill antibiotic-resistant bacteria, which are a growing threat to public health. Locus Biosciences' technology is based on the CRISPR-Cas3 system, which is a powerful gene-editing tool that can be used to selectively target and destroy specific DNA sequences. The company's lead product candidate, LB-001, is a precision antibacterial product that is being developed to treat urinary tract infections caused by Escherichia coli (E. coli) bacteria. Locus Biosciences was founded in 2015 and is headquartered in Morrisville, North Carolina.